EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Effectiveness and safety of early add‐on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV ‐add study

Pedro J Serrano-Castro iD, Fernando Caballero-Martínez iD, Francisco J Campos-Lucas iD, Daniel Campos-Fernández, María José de Aguilar-Amat, Alberto García, Ariadna Gifreu, Irene Santamaría-Rodríguez, Juan José Poza iD, Manuel Toledo-Argany, Grupo de Investigadores Colaboradores

Epilepsia Open · 2025

DOI: 10.1002/epi4.70073 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Epilepsia Open, 2025. Verfasst von Pedro J Serrano-Castro und 10 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Biomédica de Málaga (IBIMA-Plataforma Bionand), Málaga, Spain. Hauptthemen laut MEDLINE: Pyrrolidinones, Anticonvulsants, Seizures, Epilepsies, Partial. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effectiveness and safety of brivaracetam (BRV) as an add‐on therapy in patients with focal onset seizures who did not achieve seizure freedom with antiseizure medication (ASM) monotherapy in routine clinical practice.

Methods

This was a retrospective, observational, multicenter study conducted across 17 neurology centers in Spain. We evaluated adult patients with focal onset epilepsy who had inadequate seizure control after at least 3 months of ASM monotherapy and were treated with dual therapy, combining BRV with their previous ASM, with the intention of maintaining this treatment for at least 6 months. Data were collected from medical records on seizure frequency, ASM doses, and adverse events (AEs), taking into account the end of this 6‐month period of dual therapy. The primary efficacy outcomes were the proportion of patients achieving ≥50% reduction in seizure frequency and those achieving seizure freedom. Safety outcomes included the incidence of treatment‐related AEs.

Results

A total of 195 patients (mean age: 43.2 years; 52.3% male; mean disease duration: 11.5 years) were included in the study. The main location of epilepsy was identified (53.8%) as the frontal lobe (27.7%). The mean number of seizures during the last 3 months of ASM monotherapy was 12.1 (SD 39.5), which decreased to 6.4 (SD 21.2) after 6 months of BRV add‐on therapy. A ≥ 50% reduction in seizure frequency was achieved by 90.8% of patients, while 49.7% reached seizure freedom. The most common AEs were related to the central nervous system, reported by 22.1% of patients, with a treatment discontinuation rate due to AEs of 12.8%. Significance BRV as an add‐on therapy is effective in reducing seizure frequency and is well‐tolerated in patients with focal onset seizures. This study supports the use of BRV as an add‐on option in patients who do not achieve adequate seizure control with ASM monotherapy. Plain Language Summary This study evaluated how effective and safe brivaracetam (BRV) is when added to another medication for patients with focal onset seizures. The results showed that adding BRV helped many patients reduce the number of seizures, and some patients stopped having seizures completely. Side effects were generally mild.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrrolidinonesAnticonvulsantsSeizuresEpilepsies, PartialHumansMaleFemaleAdultRetrospective StudiesMiddle AgedDrug Therapy, CombinationTreatment OutcomeYoung AdultSpain

Stichwörter der Autor:innen

antiseizure medicationbrivaracetamcombinationdrug therapyepilepsyfocal onset seizuresseizures

Substanzen

brivaracetamPyrrolidinonesAnticonvulsants

Autor:innen und Institutionen

  • Instituto de Investigación Biomédica de Málaga (IBIMA-Plataforma Bionand), Málaga, Spain.
  • Málaga Regional University Hospital, Málaga, Spain.
  • Departamento de Medicina y Dermatología, Universidad de Málaga, Málaga, Spain.
  • Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.
  • Health Research, Universidad Francisco de Vitoria, Madrid, Spain.
  • Vall d'Hebron University Hospital, Barcelona, Spain.

ORCID-Profile: Pedro J Serrano-Castro, Fernando Caballero-Martínez, Francisco J Campos-Lucas, Juan José Poza

Förderung

  • CSRD VA

Zitieren

APA

Serrano-Castro, P. J., Caballero-Martínez, F., Campos-Lucas, F. J., Campos-Fernández, D., de Aguilar-Amat, M. J., García, A., Gifreu, A., Santamaría-Rodríguez, I., Poza, J. J., Toledo-Argany, M., & Grupo de Investigadores Colaboradores (2025). Effectiveness and safety of early add‐on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV ‐add study. Epilepsia Open. https://doi.org/10.1002/epi4.70073

Vancouver

Serrano-Castro PJ, Caballero-Martínez F, Campos-Lucas FJ, Campos-Fernández D, de Aguilar-Amat MJ, García A, et al. Effectiveness and safety of early add‐on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV ‐add study. Epilepsia Open. 2025. doi:10.1002/epi4.70073

BibTeX
@article{SerranoCastro2025,
  author = {Serrano-Castro, Pedro J and Caballero-Martínez, Fernando and Campos-Lucas, Francisco J and Campos-Fernández, Daniel and de Aguilar-Amat, María José and García, Alberto and Gifreu, Ariadna and Santamaría-Rodríguez, Irene and Poza, Juan José and Toledo-Argany, Manuel and Grupo de Investigadores Colaboradores, Grupo de Investigadores Colaboradores},
  title = {Effectiveness and safety of early add‐on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV ‐add study},
  journal = {Epilepsia Open},
  year = {2025},
  doi = {10.1002/epi4.70073}
}
Kostenlos starten →